Orthofix Medical Inc. (OFIX)
17.55
0.18 (1.04%)
At close: Jan 14, 2025, 3:59 PM
17.51
-0.26%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 7.05 |
| Market Cap | 670.85M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -5.59 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 27.84 |
| Volume | 166,205 |
| Avg. Volume (20D) | 263,091 |
| Open | 17.46 |
| Previous Close | 17.37 |
| Day's Range | 17.31 - 17.61 |
| 52-Week Range | 12.08 - 20.73 |
| Beta | undefined |
About OFIX
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and append...
Industry Medical - Devices
Sector Healthcare
IPO Date Apr 24, 1992
Employees 1,634
Stock Exchange NASDAQ
Ticker Symbol OFIX
Website https://www.orthofix.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OFIX stock is "Strong Buy." The 12-month stock price forecast is $23, which is an increase of 31.02% from the latest price.
Buy 66.67%
Hold 33.33%
Sell 0.00%
Next Earnings Release
Orthofix Medical Inc. is scheduled to release its earnings on Mar 4, 2025,
during market hours.
Analysts project revenue of $213.30M, reflecting a 6.43% YoY growth and earnings per share of 0.07, making a -111.86% decrease YoY.
Analysts project revenue of $213.30M, reflecting a 6.43% YoY growth and earnings per share of 0.07, making a -111.86% decrease YoY.
2 months ago ·
Source
+6.53%
Orthofix Medical shares are trading higher after t...
Unlock content with
Pro Subscription
10 months ago ·
Source
+8.69%
Orthofix Medical shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY24 net sales guidance above estimates.
